Fmoc-L-beta-HAla-OH

Fmoc-L-beta-HAla-OH is an Fmoc-protected β-homologated alanine derivative in which the amino acid backbone is configured as L at the stereogenic center and the side chain is extended to a β-substituted motif. The molecule contains a fluorenylmethoxycarbonyl (Fmoc) group on the α-amino function, a free carboxylic acid for C-terminal compatibility, and a β-amino-acid framework that can influence conformational preferences during peptide assembly. The Fmoc carbamate is stable under many base-tolerant conditions used in solid-phase synthesis, while the carboxylic acid enables standard coupling chemistry after activation. The β-homologation provides a distinct spacing element relative to α-alanine, making the compound a chiral building block for constructing peptides and peptidomimetic scaffolds with altered backbone geometry and side-chain reach.

1. Peptide Synthesis

Fmoc-L-beta-HAla-OH is used in peptide building block preparation for automated solid-phase peptide synthesis and solution-phase coupling workflows. The Fmoc-protected α-amine supports controlled N-deprotection cycles, while the free carboxylic acid participates in amide bond formation using common peptide coupling activation strategies. The β-homologated alanine architecture can be incorporated as a single residue to tune local backbone spacing, affecting turn propensity and overall conformational behavior in the growing chain. Downstream, the resulting peptides can be used as research-grade analogs for backbone engineering and as intermediates for further functionalization or conjugation.

2. Unnatural Amino Acid Incorporation

Fmoc-L-beta-HAla-OH serves as a chiral amino acid intermediate for incorporating β-substituted residues into peptide sequences to generate unnatural amino acid-containing constructs. The stereodefined L configuration and the β-extended backbone element enable stereochemically consistent assembly, while the protected amine and free acid allow integration into standard peptide coupling and deprotection strategies. The altered residue geometry can be applied to modulate proteolytic stability, receptor/ligand recognition patterns, or binding-site geometry in structure-activity relationship studies. The compound's protected amino acid form also supports stepwise synthesis of libraries where β-homologated positions are systematically varied.

3. Peptidomimetics And SAR Studies

Fmoc-L-beta-HAla-OH is suitable for peptidomimetic construction in medicinal chemistry research where backbone spacing and stereochemical presentation are key design variables. The Fmoc carbamate and carboxylic acid functionality allow incorporation into peptide-like scaffolds that later undergo further derivatization such as side-chain modifications, terminal functional group transformations, or cyclization strategies. The β-homologation can create a different spatial relationship between functional motifs compared with canonical alanine residues, supporting SAR studies that correlate residue placement with binding and activity trends. The resulting analogs can function as chemical probes or scaffold components for iterative molecular design and fragment-to-lead optimization.

4. Biomolecule Labeling

Fmoc-L-beta-HAla-OH supports biomolecule modification workflows by providing a protected, stereodefined amino acid handle that can be incorporated into peptides used as labeling tags. The Fmoc-protected nitrogen enables clean assembly of N-terminus-bearing peptide conjugates, while the carboxylic acid can be transformed into activated ester or amide-forming derivatives during downstream conjugation steps. The β-extended alanine residue can help position labels at controlled distances from the recognition element, which can be relevant for affinity reagents and chemical biology probes. The compound therefore functions as a synthetic intermediate for generating labeled peptides and conjugates used in biochemical assays and analytical research.

5. Process Chemistry Intermediate

Fmoc-L-beta-HAla-OH is applied as a manufacturing-compatible chiral intermediate for producing protected β-homologated amino acid derivatives used in fine chemical synthesis. The Fmoc group provides a robust protecting-group strategy for handling and storage stability during multi-step synthesis, while the free carboxylic acid maintains a defined functional group for downstream conversion into activated coupling forms. The presence of a single stereocenter and a protected amine simplifies chiral material management in process routes that require consistent stereochemical outcomes across batches. The compound can be employed in industrial settings to supply peptide building blocks for scale-up of peptide analog production and for generating downstream intermediates used in specialty chemical production.

6. Analytical And Reference Standards

Fmoc-L-beta-HAla-OH can be used in analytical research as a structural reference for monitoring protected amino acid chemistry and peptide coupling performance. The combination of Fmoc chromophore and the β-homologated amino acid framework provides distinctive analytical signatures in chromatographic and spectrometric workflows used to verify identity, integrity, and deprotection behavior. The free carboxylic acid and the Fmoc-protected amine enable the compound to serve as a calibrant or process control material when assessing intermediate formation in peptide building block synthesis. The stereodefined L configuration further supports method development for chiral separation and for confirming stereochemical fidelity in amino acid derivative manufacturing.

1. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

2. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

3. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

5. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries